FGFR3 and neoplasm: To more efficiently inhibit tumor growth in NMIBC, combination approaches of FKA with RAS-targeting drugs (e.g., sotorasib and salirasib) [23,24], FGFR-3 inhibitor (e.g., erdafitinib) [25], and EGFR inhibitors (e.g., erlotinib and gefitinib) [26,27] should be further explored.